163 related articles for article (PubMed ID: 23240667)
21. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Olivier RI; van Beurden M
Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
[No Abstract] [Full Text] [Related]
22. Hereditary ovarian cancer--assessing risk and prevention strategies.
Pavelka JC; Li AJ; Karlan BY
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
[TBL] [Abstract][Full Text] [Related]
23. [Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy].
Levanat S; Cvok ML
Lijec Vjesn; 2010; 132(1-2):34-7. PubMed ID: 20359158
[TBL] [Abstract][Full Text] [Related]
24. Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations.
Menkiszak J; Brzosko M; Górski B; Fliciński J; Jakubowska A; Zebiełowicz D; Gronwald J; Huzarski T; Byrski T; Teresiński L; Chosia M; Rzepka-Górska I; Lubiński J
J Appl Genet; 2004; 45(2):255-63. PubMed ID: 15131356
[TBL] [Abstract][Full Text] [Related]
25. The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients.
Barak F; Milgrom R; Laitman Y; Gemer O; Rabinovich A; Piura B; Anteby E; Baruch GB; Korach J; Friedman E
Gynecol Oncol; 2010 Dec; 119(3):511-5. PubMed ID: 20850175
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
27. Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome.
Gerritzen LH; Hoogerbrugge N; Oei AL; Nagengast FM; van Ham MA; Massuger LF; de Hullu JA
Fam Cancer; 2009; 8(4):391-7. PubMed ID: 19504173
[TBL] [Abstract][Full Text] [Related]
28. Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation.
Garg K; Karnezis AN; Rabban JT
Pathology; 2018 Feb; 50(2):238-256. PubMed ID: 29373116
[TBL] [Abstract][Full Text] [Related]
29. Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.
Escobar PF; Orr JW; Grendys EC; Roland PY
Int J Gynecol Cancer; 2008; 18(4):876-7. PubMed ID: 17986247
[No Abstract] [Full Text] [Related]
30. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
31. Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma.
Garg K; Soslow RA
J Clin Pathol; 2009 Aug; 62(8):679-84. PubMed ID: 19638537
[TBL] [Abstract][Full Text] [Related]
32. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Spannuth WA; Thaker PH; Sood AK
Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
[TBL] [Abstract][Full Text] [Related]
33. Lynch syndrome.
Backes FJ; Cohn DE
Clin Obstet Gynecol; 2011 Jun; 54(2):199-214. PubMed ID: 21508689
[TBL] [Abstract][Full Text] [Related]
34.
Chung SH; Woldenberg N; Roth AR; Masamed R; Conlon W; Cohen JG; Joines MM; Patel MK
Radiographics; 2020; 40(2):306-325. PubMed ID: 32031911
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
36. [Cancer genetics: estimation of the needs of the population in France for the next ten years].
Bonaïti-Pellié C; Andrieu N; Arveux P; Bonadona V; Buecher B; Delpech M; Jolly D; Julian-Reynier C; Luporsi E; Noguès C; Nowak F; Olschwang S; Orsi F; Pujol P; Saurin JC; Sinilnikova O; Stoppa-Lyonnet D; Thépot F
Bull Cancer; 2009 Sep; 96(9):875-900. PubMed ID: 19751997
[TBL] [Abstract][Full Text] [Related]
37. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
39. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
Dombernowsky SL; Weischer M; Freiberg JJ; Bojesen SE; Tybjaerg-Hansen A; Nordestgaard BG
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2339-42. PubMed ID: 19661094
[TBL] [Abstract][Full Text] [Related]
40. [Molecular diagnostic techniques in gynaecologic cancer].
Salvesen HB; Iversen OE; Tropé C
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3120-3. PubMed ID: 16299569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
